发现安全的COX-2抑制剂:通过平衡的COX抑制来实现减少结肠炎副作用
Xinlin Zhu1, Qin Li2, Junhui Wu3
1Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, 310014, China.
ChemMedChem
|February 27, 2025
概括
研究人员开发了一种新的,平衡的循环氧化酶-2 (COX-2) 抑制剂,化合物21u2009d,显示出强大的抗炎作用. 这种新的候选药物有效地减少了急性结肠炎模型中的损伤,为治疗炎症提供了更安全的替代方案.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 不平衡的循环氧化酶-2 (COX-2) 抑制的严重不良影响阻碍了抗炎药物的开发.
- 目前的策略转向适度选择性的COX-2抑制剂.
- 由于COX-1和COX-2之间的结构相似性,这给设计带来了挑战和机遇.
研究的目的:
- 为了发现新的,更安全的COX-2抑制剂.
- 为了评估化合物21 u2009d.d.的抗炎潜力.
- 评估化合物21 u2009d. 的平衡抑制特征.
主要方法:
- 新型COX-2抑制剂的合成和表征.
- 在体外酶测试以确定抑制功效和选择性 (IC50值).
- 在硫酸 (DSS) 诱导的急性结肠炎模型中对抗炎症功效的体内评估.
主要成果:
- 化合物21 u2009d被确定为一种强效和平衡的COX-2抑制剂 (IC50 = 1.35 μM,选择性比 = 22.34).
- 21 u2009d在DSS诱导的大肠炎模型中显著降低了组织学损伤.
- 已证明对急性结肠炎有强大的保护作用,表明治疗潜力.
结论:
- 化合物21 u2009d是新一代更安全的抗炎药物的有希望的候选者.
- 均衡的COX-2抑制是减轻不良影响的可行策略.
- 对于21 u2009d的治疗应用,需要对其进行进一步的研究.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
326
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
326
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
455
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
455
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
397
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
397
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
350
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
350


